WebCinclus Pharma Appoints Christer Ahlberg as Chief Executive Officer Thu, Feb 25, 2024 08:30 CET. Stockholm, Sweden 25[th] February 2024: Cinclus Pharma Holding AB … WebMay 20, 2024 · Christer Ahlberg, CEO Phone: +46 70 675 33 30 e-mail: [email protected] Charlotte Stjerngren, IR Phone: +46 70 876 87 87 e-mail: [email protected] About Cinclus Pharma and its lead candidate drug linaprazan glurate (former X842)
Christer Ahlberg - CEO - Cinclus Pharma Business Profile
WebView Christer Ahlberg's business profile as CEO at Cinclus Pharma. Find Christer's email address, mobile number, work history, and more. WebFeb 24, 2024 · Christer Ahlberg, CEO, Sedana Medical Mobile: +46 70 675 33 30 E-mail: [email protected] Thomas Eklund, Chairman of the Board, Sedana Medical Mobile: +46 70 824 20 25 E-mail: [email protected] Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm. michelson shoes lexington ma hours
Christer Ahlberg - Biography - MarketScreener.com
WebThe US Food and Drug Administration (FDA) has granted a Qualified Infectious Disease Product (QIDP) designation for Cinclus Pharma’s leading drug candidate… WebAug 18, 2024 · Christer Ahlberg, CEO Phone: +46 70 675 33 30 e-mail: [email protected] Peter Unge, CMO Phone: +46 70 576 37 80 e-mail: [email protected] Andrew Thompson, Business... WebCinclus Pharma is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. Lists Featuring This Company Scandinavia Companies With Less Than $1B in Revenue (Top 10K) michelson shoes needham